Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug testing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,069 result(s) found for: Drug testing. Displaying page 4 of 104.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002392-10 Sponsor Protocol Number: S59302 Start Date*: 2017-02-02
    Sponsor Name:UZ Leuven
    Full Title: Reconsolidation interference versus retrieval interference as the basis for experimental amnesia in humans – The effect of drug state at memory retrieval
    Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test wether the internal drug ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002894-39 Sponsor Protocol Number: 8273-CL-0302 Start Date*: 2016-03-11
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating M...
    Medical condition: Non-small Cell Lung Cancer Tumors
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    18.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Prematurely Ended) NL (Prematurely Ended) ES (Temporarily Halted) PT (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000196-24 Sponsor Protocol Number: 402-C-1504 Start Date*: 2016-07-04
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
    Medical condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003241-26 Sponsor Protocol Number: EP0093 Start Date*: 2018-09-04
    Sponsor Name:UCB Biopharma SPRL
    Full Title: An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy
    Medical condition: Focal-Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BG (Completed) FR (Completed) LT (Completed) BE (Completed) PT (Prematurely Ended) EE (Completed) NL (Completed) DK (Completed) AT (Completed) GR (Completed) FI (Completed) NO (Completed) SE (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-004044-28 Sponsor Protocol Number: AKF-396 Start Date*: 2020-12-18
    Sponsor Name:University of Southern Denmark
    Full Title: Flucloxacillin as an inducer of CYP-enzymes
    Medical condition: Healthy volunteers. (Flucloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by flucloxacillin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011538-93 Sponsor Protocol Number: Maraviroc –switch Start Date*: 2010-06-07
    Sponsor Name:Imperial College London
    Full Title: A prospective, randomised study to access safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters over 48 weeks in HIV-1 infected subjects undergoing a switch in...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004547-77 Sponsor Protocol Number: RN03-CP-0001 Start Date*: 2020-06-09
    Sponsor Name:ReNeuron Ltd
    Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP)
    Medical condition: Retinitis Pigmentosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-007338-23 Sponsor Protocol Number: CLCI699A2216 Start Date*: 2009-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks...
    Medical condition: resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2020-002869-34 Sponsor Protocol Number: AT-03A-001 Start Date*: 2020-08-11
    Sponsor Name:Atea Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004444-29 Sponsor Protocol Number: RID-TB:Treat Start Date*: 2020-11-25
    Sponsor Name:University College London
    Full Title: An open-label, multi-centre, randomised controlled trial evaluating the effects of short-course rifapentine-based regimens and additional adherence support on LTBI treatment adherence and completio...
    Medical condition: Latent Tuberculosis infection (LTBI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10065048 Latent tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-004025-14 Sponsor Protocol Number: GS-US-380-1844 Start Date*: 2016-02-18
    Sponsor Name:Gilead Science, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of G...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002514-12 Sponsor Protocol Number: FACILE Start Date*: 2019-11-12
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI - ONLUS
    Full Title: Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in combination with a non steroidal aromatase inhibitor in elderly patients with hormone receptor positive...
    Medical condition: HR+, HER2 negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003348-10 Sponsor Protocol Number: TAK-755-3002 Start Date*: 2020-11-17
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and o...
    Medical condition: congenital Thrombotic thrombocytopenic purpura (TTP)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) ES (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004497-10 Sponsor Protocol Number: CT-P13-3.4 Start Date*: 2014-07-16
    Sponsor Name:Celltrion, Inc.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease
    Medical condition: Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10058815 Crohn's disease acute episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) RO (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-005487-26 Sponsor Protocol Number: AI468-038 Start Date*: 2015-07-03
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000654-59 Sponsor Protocol Number: MT-2-02 Start Date*: 2019-06-25
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral...
    Medical condition: Cerebral X-linked Adrenoleukodystrophy (cALD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051260 Adrenoleukodystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001081-38 Sponsor Protocol Number: ARCT-810-03 Start Date*: 2021-12-23
    Sponsor Name:Arcturus Therapeutics, Inc.
    Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004553-17 Sponsor Protocol Number: CC-4047-MMM-001 Start Date*: 2007-04-24
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT O...
    Medical condition: Myelofibrosis with myeloid metaplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028538 Myelofibrosis with myelometaplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) AT (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001907-19 Sponsor Protocol Number: PILOT-PREXOL Start Date*: 2019-07-03
    Sponsor Name:Region Skåne
    Full Title: Pramipexole augmentation to target anhedonia in depression - a pilot study
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10002511 Anhedonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005773-27 Sponsor Protocol Number: APHP190353 Start Date*: 2021-03-09
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)
    Full Title: BARIcitinib Cognitive Emotional and Neural signaTuRE BARICENTRE
    Medical condition: Patients with rheumatoid arthritis and indication of baricitinib treatment according to a rheumatologist
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 18:46:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA